# This Page Is Inserted by IFW Operations and is not a part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

NO.875 P.1/14

I hereby certify that this correspondence is being facsimile transmitted to OIPE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 to facsimile number 1-703-746-9195

PATENT

Attorney Docket No.: 015270-005912US Client Ref. No.: 209-US-NEW6C2

6096

Confirmation No.:

Application No.: 09/724,575

Applicant:

Dale B. Schenk

Filed:

November 28, 2000

TC/A.U.:

1600/1647

Examiner:

Christopher Nichols

Docket No.:

015270-005912US

Customer No.:

20350

Office of Initial Patent Examination United States Patent and Trademark Office

#### REQUEST FOR CORRECTED FILING RECEIPT

Sir:

Issuance of a corrected filing receipt is respectfully requested. Attached hereto is a marked-up copy of the Filing Receipt mailed by the Patent Office on May 16, 2001.

Please correct the GRP ART UNIT information; delete "1632" and replace it with "1647".

Please correct the ATTY.DOCKET.NO information; delete "00209-US-NEW6C2" and replace it with "15270-005912".

Please correct the correspondence address information. (See the copy of the Change of Correspondence Address PTO/SB/122 filed under separate cover on December 29, 2003, attached hereto.)

Application No. 09/724,570
Request for Corrected Filing Receipt dated December 30, 2003

PATENT

Delete:

Nina M Ashton Elan Pharmaceuticals Inc 800 Gateway Boulevard South San Francisco, CA 94080

and replace it with:

TOWNSEND AND TOWNSEND AND CREW TWO EMBARCADERO CENTER EIGHTH FLOOR SAN FRANCISCO, CA 94111-3834

Please correct the Domestic Priority data as claimed by applicant. (See the copy of the Initial Application Data Sheet filed on May 21, 2003, attached hereto.)

Add the following to the existing domestic priority data:

THIS APPLICATION IS ALSO A CON OF 09/585,817 06/01/2000 WHICH IS A CIP OF 09/580,015 05/26/2000 WHICH IS A CIP OF 09/322,289 05/28/1999 WHICH IS A CIP OF 09/201,430 11/30/1998 WHICH CLAIMS BENEFIT OF 60/080,970 04/07/1998 AND WHICH CLAIMS BENEFIT OF 60/067,740 12/02/1997

Please correct the Title; delete "Pharmaceutical compositions and methods for treatment of amyloid diseases" and replace it with "Prevention and Treatment of Amyloidogenic Diseases". (See the copy of the Preliminary Amendment filed March 13, 2002, attached hereto.)

e L'alli

Application No. 09/724,570
Request for Corrected Filing Receipt dated December 30, 2003

PATENT

Applicant believes no fee is required for submission of this request. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the previously noted deposit account.

Respectfully submitted.

Rosemarie L. Celli Reg. No. 42,397

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834

Tel: 650-326-2400 Fax: 650-326-2422

RLC 60109918 v1

Page 1 of 4



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/724,575	11/28/2000	1632			16	57	5

1647

:15270-005912

**CONFIRMATION NO. 6096** 

FILING RECEIPT

- Nine M: Ashton --- Elan-Pharmaceuticals, Inc.-

-800 Caleway Boulevard

South San Francisco, CA 94080

TOWNSEND AND TOWNSEND AND CREW

TWO EMBARÇADERO CENTER

EIGHTH FLOOR

SAN FRANCISCO, CA 94111-3834

Date Mailed: 05/16/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Pees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filling Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filling Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filling Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filling Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Dale B. Schenk, Burlingame, CA;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/585,817 06/01/2000 WHICH CLAIMS BENEFIT OF 60/137,010 06/01/1999

Foreign Applications

If Required, Foreign Filing License Granted 05/15/2001

Projected Publication Date: N/A

Non-Publication Request: No

Early Publication Request: No

THIS APPLICATION IS ALSO A CON OF 09/585,817 06/01/2000

WHICH IS A CIP OF 09/580,015 05/26/2000

WHICH IS A CIP OF 09/322,289 05/28/1999

WHICH IS A CIP OF 09/201,430 11/30/1998

WHICH CLAIMS BENEFIT OF 60/080,970 04/07/1998

AND WHICH CLAIMS BENEFIT OF 60/067,740 12/02/1997

Titi

-Pharmaceutical compositions and methods for treatment of amyloid diseases --

Prevention and Treatment of Amyloidogenic Diseases

	i		PTO/SB/122	(00
CHANGE OF	Applicatio	n Number	09/724,575	┿
CORRESPONDENCE ADDRESS	Filling Dat	ie	November 28, 2000	+
Application	First Nam	ed inventor	Dale B. Schenk	+
Address to: Commissioner for Patents	Art Unit		1647	_
P.O. Box 1450	Examiler	Name	Christopher Nichols	_
Alexandria, VA 22313-1450	Allomy	ocket Number	015270-005912US	<u></u>
Please change the Correspondence Address for the all Customer Number: 20150	bove-identified p	atent application to	):	
Flrm or Individual Name				
Address				1
Address				1
Country	State		ZIP	+
Telephone		ax		+
Applicant/Inventor.  Assignee of record of the enderment under 37 CFR 3.  Attorney or agent of record.  Registered practitioner named executed oath or declaration.	.73(b) is enclo Registration	Number <u>42,35</u>	97 tter in an application without an	
yped or Printed Name				
ignature Assurance a	2. a	U.		
pate December 29, 2003	•	The state of the s		
OTE: Signatures of all the inventors or assignees of nuttiple forms if more than one signature is required, a	ecord of the enli	re interest or their	representative(s) are required. Subm	ilt
	EB DEIOW .	•		1
Total of 1 forms are submitted.				

## **Application Data Sheet**

### **Application Information**

Application number:

Filing Date::

11/28/0

Application Type::

Regulation

Subject Matter::

Utility

Number of copies of CDs::

Sequence Submission::

Paper

Computer Readable Form (CRF)?::

Yes

Number of copies of CRF::

1

Title::

Prevention and Treatment of Amyloid Diseases

Attorney Docket Number::

015270-005912US

Request for Early Publication::

No ·

Request for Non-Publication::

No

**Total Drawing Sheets::** 

16

Small Entity?::

No

Petition included?::

Yes

**Petition Type::** 

Request for Ext. of Time Under 37 CFR 1.136(a)

Secrecy Order in Parent Appl.::

No

## **Applicant Information**

Applicant Authority Type::

Inventor

Primary Citizenship Country::

US

Status::

Full Capacity

Given Name::

Dale

Middle Name::

В.

Family Name::

Schenk

Name Suffix::

City of Residence::

Page 1

Burlingame

Initial 5/20/03

State or Province of Residence::

CA

Country of Residence::

US

Street of Mailing Address::

1542 Los Altos Drive

City of Mailing Address::

Burlingame

State or Province of mailing address:

Country of mailing address::

940101 Postal or Zip Code of mailing address::

Correspondence information

Correspondence Customer Number::

20350

R presentative information

Representative Customer Number::

20350

**Domestic Priority Information** 

Appl	icat	ion::

Continuity Type::

Parent Application::

Parent Filing Date::

#### This Application

Continuation of

09/585,817

06/01/00

09/585,817

An application claiming the benefit under 35 USC

119(e)

60/134,010

06/01/99

## This Application

Continuation

09/585,817 09/580,015 06/01/00

## 09/585.817 09/580,015

Continuation-in-part of

05/26/00 09/322,289 05/28/99

09/322,289

Continuation-in-part of An application claiming

Continuation-in-part of

11/30/98 09/201,430

09/201,430

the benefit under 35 USC 119(e)

60/080,970

04/07/98

09/201,430

An application claiming the benefit under 35 USC

60/067,740

119(e)

Page 2

Initial 5/20/03

## **Assignee Information**

Assignee Name:: Elan Pharmaceuticals, Inc.

Street of mailing address:: 800 Gateway Boulevard

City of mailing address:: South San Frangisco

State or Province of mailing address:: California

Country of mailing address:: US


Postal or Zip Code of mailing address::

USPTO->

658 326 2422 RightFAX


Page 881

TO: Auto-reply fax to 15503262422 COMPANY



# Auto-Reply Facsimile Transmission

MI 8: 45



TO:

Fax Sender at 16503262422

Fax Information Date Received: Total Pages;

3/13/02 10:04:35 PM [Eastern Standard Time]
4 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 702.04 et seq.

Received Cover Page

MAR.L3.20002 Atty Docket No. 152701-0059121 1-703-872-9306 PTO FAX NO.: Group Art Unit 1516 Domine Robert M. DeWitty ATTENTION; OFFICIAL COMMUNICATION FOR THE PERSONAL ATTENTION OF EXAMINER Robert M. DeWitty CERTIFICATION OF FACSIMILE TRANSMISSION I becoby certify that the following documents in to Application of Dale B. School, Application 09/124,575, Glad November 28, 2000 for PREVENTING AND TREATMENT AMYLOTOOGENIC DISEASE is being fastimile ton on the data shown below. Decument(s) Attached L. Preliminary Amendment (3 pages), PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILB AT (650) 326-2422 TOWNSEND and TOWNSEND and CREW LLP Two Embanadaro Contr. 8th Floor San Francisco, Ca. 94111-9834 Telephone: 650-326-2400 Fac: 650-326-2422 Received from < 1658/3282422 > 31 JI (2002 10:00:25 PM (Eastern Spandard Time)

P. 1

COMMUNICATION RESULT REPORT ( MAR. 13.200

7:06PM) \* \* \*

ADDRESS (GROUP)

##88115#17038729306#

TTI TOWNSEND&TOWNSEND
PAGE

WHENCY TX

##88115#17038729306#

OK
P. 4/4

REASON FOR ERROR E-1) HANG UP OR LINE FAIL E-3) NO ANSWER

E-2) BUSY E-4) NO FACSIMILE CONNECTION

PTO FAX NO.:

1-703-872-9306

ATTENTION:

Examiner Robert

Group Art Unit 1516

Atty Docket No. 15270J-005912\]JS

OFFICIAL COMMUNICATION

FOR THE PERSONAL ATTENTION OF

**EXAMINER Robert M. DeWitty** 

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application of Dale B, Schenk, Application To. 09/724,575, filed November 28, 2000 for PREVENTING AND TREATMENT OF AMYLODOGENIC DISEASE is being facsimile transmitted to the Patent and Trademark Office

on the date shown below.

PAGE 10/14 \* RCVD AT 12/30/2003 8:09:17 PM [Eastern Standard Time] \* SVR:USPTO-EFXRF-2/0 \* DNIS:7469195 \* CSID:16503262422 \* DURATION (mm-ss):02-52

Atty Docket No. 15270J-005912US

PTO FAX NO.:

1-703-872-9306

ATTENTION:

Examiner Robert M. DeWitty

Group Art Unit 1616

# OFFICIAL COMMUNICATION

# FOR THE PERSONAL ATTENTION OF

# **EXAMINER Robert M. DeWitty**

#### CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that the following documents in re Application & Dale B. Schenk, Application No. 09/724,575, filed November 28, 2000 for PP NENTING AND TREATMENT OF AMYLOIDOGENIC DISEASE is being facsimile traditionisted to the Patent and Trademark Office on the date shown below.

Document(s) Attached

1. Preliminary Amendment (3 pages).

Number of pages being transmitted, including this page: 4

Dated:

Rosemarie L. Celli

PLEASE CONFIRM RECEIPT OF THIS PAPER BY RETURN FACSIMILE AT (650) 326-2422

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, CA 94111-3834 Telephone: 650-326-2400

Fax: 650-326-2422

PA 3207045 vl

I hereby certify that this correspondence is being sent by facsimile transmission to:

Attorney Docket No.: 15270J-005912US

Client Ref. No.: 209-US-NEW6C2

1-703-872-9306

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit:

In re application of:

Dale B. Schenk

Application No.: 09/724,575

Filed: November 28, 2000

For: PREVENTING AND TREATMENT

OF AMYLOIDOGENIC DISEASE

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the following amendments and remarks.

## IN THE SPECIFICATION:

Please replace the title section of the specification with the following replacement title section.

Prevention and Treatment of Amyloidogenic Disease

#### REMARKS

Support for the amendment to the title may be found throughout the specification, e.g., at page 22, lines 12-14, claim 11, and claim 29.

1616

PRELIMINARY AMENDMENT

Dale B. Schenk

Application No.: 09/724,575

Page 2

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400.

Respectfully submitted

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834 Tel: (650) 326-2400

Fax: (650) 326-2422 R1C:11h

PA 3206139 v1

Dale B. Schenk

Application No.: 09/724,575

Page 3

PATENT

# VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please replace the title section of the specification with the following replacement title section.

Prevention and Treatment of Amyloidogenic Disease [Pharmaceutical Compositions And Methods For Treatment Of Amyloid Diseases]

PA 3206139 v1

